Foghorn Therapeutics (FHTX) Competitors $3.88 +0.07 (+1.84%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$3.88 0.00 (-0.13%) As of 03/27/2025 04:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock FHTX vs. RCKT, XNCR, ZYME, XERS, PAHC, GYRE, OCS, REPL, COGT, and DAWNShould you be buying Foghorn Therapeutics stock or one of its competitors? The main competitors of Foghorn Therapeutics include Rocket Pharmaceuticals (RCKT), Xencor (XNCR), Zymeworks (ZYME), Xeris Biopharma (XERS), Phibro Animal Health (PAHC), Gyre Therapeutics (GYRE), Oculis (OCS), Replimune Group (REPL), Cogent Biosciences (COGT), and Day One Biopharmaceuticals (DAWN). These companies are all part of the "pharmaceutical products" industry. Foghorn Therapeutics vs. Rocket Pharmaceuticals Xencor Zymeworks Xeris Biopharma Phibro Animal Health Gyre Therapeutics Oculis Replimune Group Cogent Biosciences Day One Biopharmaceuticals Rocket Pharmaceuticals (NASDAQ:RCKT) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, community ranking, media sentiment, risk, analyst recommendations, valuation and institutional ownership. Do insiders and institutionals hold more shares of RCKT or FHTX? 98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. Comparatively, 61.5% of Foghorn Therapeutics shares are owned by institutional investors. 28.5% of Rocket Pharmaceuticals shares are owned by insiders. Comparatively, 9.1% of Foghorn Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community believe in RCKT or FHTX? Rocket Pharmaceuticals received 355 more outperform votes than Foghorn Therapeutics when rated by MarketBeat users. Likewise, 73.33% of users gave Rocket Pharmaceuticals an outperform vote while only 64.06% of users gave Foghorn Therapeutics an outperform vote. CompanyUnderperformOutperformRocket PharmaceuticalsOutperform Votes39673.33% Underperform Votes14426.67% Foghorn TherapeuticsOutperform Votes4164.06% Underperform Votes2335.94% Is RCKT or FHTX more profitable? Rocket Pharmaceuticals has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -357.53%. Foghorn Therapeutics' return on equity of 0.00% beat Rocket Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Rocket PharmaceuticalsN/A -62.62% -54.17% Foghorn Therapeutics -357.53%N/A -30.98% Does the media prefer RCKT or FHTX? In the previous week, Foghorn Therapeutics had 1 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 6 mentions for Foghorn Therapeutics and 5 mentions for Rocket Pharmaceuticals. Rocket Pharmaceuticals' average media sentiment score of 1.10 beat Foghorn Therapeutics' score of 0.78 indicating that Rocket Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rocket Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Foghorn Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, RCKT or FHTX? Rocket Pharmaceuticals has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500. Comparatively, Foghorn Therapeutics has a beta of 3.13, meaning that its share price is 213% more volatile than the S&P 500. Which has stronger valuation & earnings, RCKT or FHTX? Foghorn Therapeutics has higher revenue and earnings than Rocket Pharmaceuticals. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRocket PharmaceuticalsN/AN/A-$245.60M-$2.73-2.89Foghorn Therapeutics$22.60M9.55-$98.43M-$1.65-2.35 Do analysts prefer RCKT or FHTX? Rocket Pharmaceuticals presently has a consensus target price of $43.00, suggesting a potential upside of 445.69%. Foghorn Therapeutics has a consensus target price of $13.17, suggesting a potential upside of 239.35%. Given Rocket Pharmaceuticals' higher possible upside, research analysts plainly believe Rocket Pharmaceuticals is more favorable than Foghorn Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rocket Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.92Foghorn Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00 SummaryFoghorn Therapeutics beats Rocket Pharmaceuticals on 10 of the 18 factors compared between the two stocks. Remove Ads Get Foghorn Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FHTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FHTX vs. The Competition Export to ExcelMetricFoghorn TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$215.78M$6.91B$5.64B$8.06BDividend YieldN/A2.73%4.57%4.01%P/E Ratio-2.027.2023.1419.03Price / Sales9.55226.01384.1193.17Price / CashN/A65.6738.1634.64Price / Book-2.126.476.954.33Net Income-$98.43M$141.90M$3.20B$247.06M7 Day Performance-4.20%-3.20%-2.28%-0.37%1 Month Performance-20.00%-5.64%2.88%-3.85%1 Year Performance-42.18%-7.47%10.87%1.27% Foghorn Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FHTXFoghorn Therapeutics2.653 of 5 stars$3.88+1.8%$13.17+239.3%-38.2%$215.78M$22.60M-2.02120RCKTRocket Pharmaceuticals4.6678 of 5 stars$8.73+3.6%$43.00+392.6%-71.1%$930.88MN/A-3.17240Positive NewsXNCRXencor3.4825 of 5 stars$12.95-1.9%$34.38+165.4%-48.7%$912.48M$110.49M-4.05280ZYMEZymeworks2.6528 of 5 stars$13.05+2.6%$21.00+60.9%+21.5%$907.98M$76.30M-8.70460Insider TradePositive NewsXERSXeris Biopharma3.2728 of 5 stars$5.87+1.0%$5.92+0.8%+176.0%$903.63M$203.07M-13.04290High Trading VolumePAHCPhibro Animal Health3.9549 of 5 stars$22.06+0.7%$21.00-4.8%+66.0%$893.50M$1.11B45.961,860Analyst DowngradeShort Interest ↓Positive NewsGYREGyre Therapeutics0.2 of 5 stars$9.21-5.1%N/A-48.1%$862.17M$105.76M184.2040News CoverageHigh Trading VolumeOCSOculis1.9815 of 5 stars$19.61+0.2%$29.50+50.4%+62.9%$856.21M$980,000.00-10.162Short Interest ↑REPLReplimune Group3.8551 of 5 stars$11.05+2.1%$19.43+75.8%+26.7%$851.02MN/A-3.60210Positive NewsCOGTCogent Biosciences2.4045 of 5 stars$7.40+3.4%$14.43+95.0%+1.4%$842.49MN/A-2.9880Positive NewsDAWNDay One Biopharmaceuticals2.8166 of 5 stars$8.31+1.0%$34.57+316.0%-48.1%$842.26M$131.16M-8.0760Analyst Forecast Remove Ads Related Companies and Tools Related Companies Rocket Pharmaceuticals Competitors Xencor Competitors Zymeworks Competitors Xeris Biopharma Competitors Phibro Animal Health Competitors Gyre Therapeutics Competitors Oculis Competitors Replimune Group Competitors Cogent Biosciences Competitors Day One Biopharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FHTX) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredAI Boom Takes a Shocking Turn…A potentially historic moment for retirement Let's make the most of this market together. Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Foghorn Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Foghorn Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
